Yenny Angela

Carl Neuberg Str. 1
Hannover, NI 30625, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

Solitary gallbladder metastases by malignant melanoma.

Solitary gallbladder metastases by malignant melanoma.

Journal: Nuklearmedizin. Nuclear medicine
Published: June 02, 2026

Nemolizumab for Pruritus Control in Cutaneous T-Cell Lymphoma: A Case Series.

Nemolizumab for Pruritus Control in Cutaneous T-Cell Lymphoma: A Case Series.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: February 18, 2026

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.

Journal: European journal of cancer (Oxford, England : 1990)
Published: January 25, 2026

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

Journal: Cancers
Published: January 13, 2026

Perioperative PD-1-inhibition in melanoma patients - a retrospective analysis from eight German skin cancer centers.

Perioperative PD-1-inhibition in melanoma patients - a retrospective analysis from eight German skin cancer centers.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: January 07, 2026

Complete Regression of bilateral Choroidal Metastases secondary to a Cutaneous Melanoma under Immunotherapy.

Complete Regression of bilateral Choroidal Metastases secondary to a Cutaneous Melanoma under Immunotherapy.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: December 10, 2025

A composite score of serum cytokines enables early identification of patients at high risk for irAEs under immune checkpoint inhibition.

A composite score of serum cytokines enables early identification of patients at high risk for irAEs under immune checkpoint inhibition.

Journal: Frontiers in immunology
Published: October 27, 2025

Alcian blue-positive stromal phenotype in basal cell carcinoma is associated with progression on first-line hedgehog inhibitors.

Alcian blue-positive stromal phenotype in basal cell carcinoma is associated with progression on first-line hedgehog inhibitors.

Journal: The journal of pathology. Clinical research
Published: October 22, 2025

Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.

Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.

Journal: European journal of cancer (Oxford, England : 1990)
Published: April 24, 2025

Machine learning-derived serum protein signatures as biomarkers for checkpoint inhibition in melanoma.

Machine learning-derived serum protein signatures as biomarkers for checkpoint inhibition in melanoma.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 14, 2025

Chronic rhinosinusitis during immune checkpoint inhibition in melanoma patients.

Chronic rhinosinusitis during immune checkpoint inhibition in melanoma patients.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: April 09, 2025

Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial.

Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial.

Journal: The British journal of dermatology
Published: April 08, 2025
Showing 1-12 of 33

Last Updated: 09/26/2026